Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Zyomyx Patents; Zyomyx to Help Develop New Protein Chip Applications

NEW YORK, Dec. 1 (GenomeWeb News) - Invitrogen has licensed several protein-chip patents from Zyomyx and has signed an R&D deal with the company to develop new products, Invitrogen said yesterday.


Under the agreement, Invitrogen obtained the rights to specific fields of use for more than 30 protein microarray patents held by Zyomyx. Invitrogen plans to use these patents to develop additional applications for its own protein arrays, called ProtoArray, which resulted from its acquisition of Protometrix earlier this year. Through an R&D agreement, Zyomyx will contribute to the development of these new products.


"The Zyomyx development processes are very complementary to our ProtoArray products, and by licensing rights to relevant Zyomyx intellectual property we are making it possible for Invitrogen researchers to develop proprietary processes and applications for our unique protein microarrays that will expand their utility and accessibility," Invitrogen CEO Greg Lucier said in a company statement.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.